hu6ED94A Frozen Validation Report
344 PRS models · 1,636 protein predictions · 142 candidate variants. This static snapshot is generated from the public report JSON artifact.
Overview-first report: suggested next steps are shown before technical PRS and protein tables. Genetic evidence is not diagnostic by itself.
Clinical Variant Status
✓No confirmed pathogenic
Immune and autoimmune pattern
near-term focus
Your strongest overall theme is immune-system sensitivity, with several autoimmune and inflammatory signals pointing in the same direction.
Full explanation
Several genetic signals cluster around immune activity, including joint-related autoimmunity, lupus-like immune pathways, inflammatory bowel disease, celiac-type immune response, type 1 diabetes background, and general inflammation.
The protein-pathway evidence also leans immune-heavy. These are not measured blood tests, but they suggest that inherited immune signaling may be one of the more active parts of your profile.
The important nuance is that this does not mean you have an autoimmune condition. It means that unexplained inflammatory symptoms would deserve more context than they might in a lower-signal profile.
This becomes worth discussing if there are persistent joint swelling, mouth ulcers, unexplained rashes, bowel inflammation, unusual fatigue with inflammation markers, strong family history of autoimmunity, or abnormal immune-related labs.
What to watch forKeep this as a useful review area if persistent inflammatory symptoms, autoimmune family history, or unusual immune-related labs ever appear.
Show technical evidence
Risk-score evidence
- lupus: risk percentile 99%, coverage 100%, PGS001870.
- systemic lupus erythematosus: risk percentile 94.6%, coverage 99%, PGS000771.
- rheumatoid arthritis: risk percentile 89.3%, coverage 99%, PGS004010.
- type 1 diabetes: risk percentile 95.4%, coverage 100%, PGS004147.
- inflammatory bowel disease: risk percentile 93.1%, coverage 100%, PGS004013.
- celiac disease: risk percentile 92.5%, coverage 100%, PGS001856.
Protein pathway context
- CLEC7A: predicted level percentile 99.4%, R2 0.5374; pathway context only.
- LILRB5: predicted level percentile 96.9%, R2 0.7926; pathway context only.
- MICB_MICA: predicted level percentile 96.7%, R2 0.7159; pathway context only.
- IL1RAP: predicted level percentile 93.7%, R2 0.706; pathway context only.
- IL1RL1: predicted level percentile 94%, R2 0.5009; pathway context only.
- CTSH: predicted level percentile 91.7%, R2 0.6192; pathway context only.
Candidate variants
- Variant rs10892279 GG: snpedia_context.
- Variant rs10484561 TT: snpedia_context.
- LOC101929727 rs10509540 TT: snpedia_context.
- Variant rs10865331 GG: snpedia_context.
Thyroid and endocrine watch
useful to review
Thyroid-related signals stand out and overlap with broader immune and hormone-regulation context.
Full explanation
The thyroid cluster is not just one isolated signal. There are multiple thyroid-related findings, including both low-function and high-function thyroid backgrounds, plus overlap with immune-driven endocrine patterns.
That kind of mixed thyroid direction is common in genetics because the shared tendency is often immune regulation around the thyroid, not a single guaranteed thyroid outcome.
The hormone-pathway protein evidence adds context, but it should not be read as a measured hormone result. Real thyroid status still depends on symptoms and blood testing.
This becomes worth reviewing if there are changes in energy, weight, heat or cold tolerance, heart rate, bowel pattern, mood, hair or skin texture, fertility context, family history of thyroid disease, or thyroid lab changes.
What to watch forIf thyroid-like symptoms or thyroid lab abnormalities arise, mention that your inherited profile has a notable thyroid and immune overlap.
Show technical evidence
Risk-score evidence
- hypothyroidism: risk percentile 98.4%, coverage 100%, PGS001816.
- hypothyroidism myxoedema: risk percentile 97%, coverage 93%, PGS000965.
- thyrotoxicosis with or without goiter: risk percentile 88.9%, coverage 100%, PGS001815.
- nontoxic multinodular goiter: risk percentile 9%, coverage 100%, PGS001814.
- other non toxic goitre: risk percentile 10.7%, coverage 92%, PGS000928.
- type 1 diabetes: risk percentile 95.4%, coverage 100%, PGS004147.
Protein pathway context
- INSL3: predicted level percentile 87.8%, R2 0.7312; pathway context only.
- FSHB: predicted level percentile 86.5%, R2 0.6068; pathway context only.
- SMPDL3A: predicted level percentile 97.6%, R2 0.5001; pathway context only.
Candidate variants
- MIR22,MIR22HG,WDR81 rs11078597 TT: snpedia_context.
- LOC101929727 rs10509540 TT: snpedia_context.
Airway, allergy, and smoke context
near-term focus
Allergy, eczema, asthma, and smoke-related lung context cluster together, making airway and skin-barrier sensitivity a meaningful theme.
Full explanation
The allergy and airway part of the profile is fairly coherent. Atopic disease, eczema, dermatitis, asthma, and related immune signals all point toward a tendency for reactive barrier and airway pathways.
There is also smoke-related context: genetic signals connected with smoking behavior and lung cancer background appear alongside the airway findings. This does not imply current smoking or lung disease.
The practical interpretation is simple: the profile looks less forgiving of airway irritants than average, especially when immune or allergy symptoms are already present.
This becomes worth reviewing if there is wheeze, persistent cough, exercise-related breathlessness, eczema flares, repeated sinus or allergy symptoms, smoke exposure, occupational irritants, or family history of asthma or allergic disease.
What to watch forTreat smoke and airway irritants as higher-value avoidances, and review this context if allergy, asthma, or persistent respiratory symptoms show up.
Show technical evidence
Risk-score evidence
- general atopic disease: risk percentile 94.9%, coverage 98%, PGS003458.
- asthma: risk percentile 90.2%, coverage 92%, PGS001343.
- atopic eczema: risk percentile 87.5%, coverage 99%, PGS003486.
- atopic eczema or atopic disease: risk percentile 84.7%, coverage 98%, PGS003459.
- eczema dermatitis: risk percentile 80.2%, coverage 87%, PGS000944.
- lung cancer: risk percentile 98.2%, coverage 87%, PGS001392.
Protein pathway context
- SFTPD: predicted level percentile 82.2%, R2 0.5378; pathway context only.
- TLR3: predicted level percentile 14.8%, R2 0.8019; pathway context only.
- IFNGR2: predicted level percentile 83.9%, R2 0.6902; pathway context only.
- CLEC7A: predicted level percentile 99.4%, R2 0.5374; pathway context only.
Candidate variants
- Variant rs10789369 GG: snpedia_context.
Skin and sun awareness
near-term focus
Skin cancer, melanoma, sunburn, tanning, and chronic sun-effect signals make sun protection a higher-value habit.
Full explanation
The skin cluster is one of the clearer non-diagnostic themes. It includes melanoma, basal cell, non-melanoma skin cancer, childhood sunburn, chronic sun-effect, tanning, and pigmentation context.
This does not mean a skin cancer is present or inevitable. It means that ultraviolet exposure is a more important environmental factor to manage well.
The protein and DNA context add support around cell adhesion and pigmentation pathways, but the practical value is still behavioral: reduce avoidable sun damage and pay attention to changing skin features.
This becomes worth reviewing if there are changing moles, new or non-healing skin lesions, repeated sunburns, outdoor work, tanning-bed exposure, many moles, very fair skin, or a family history of melanoma or other skin cancers.
What to watch forUse consistent sun protection and bring this up if changing skin lesions, repeated burns, or family history of skin cancer are relevant.
Show technical evidence
Risk-score evidence
- skin melanoma: risk percentile 98.1%, coverage 98%, PGS003745.
- melanoma: risk percentile 89.8%, coverage 97%, PGS003430.
- basal cell carcinoma: risk percentile 92.8%, coverage 100%, PGS003416.
- non melanoma skin cancer: risk percentile 90.9%, coverage 89%, PGS001040.
- childhood sunburn: risk percentile 81.9%, coverage 87%, PGS001257.
- skin changes due to chronic exposure to nonionising radiation: risk percentile 80%, coverage 84%, PGS000950.
Protein pathway context
- CEACAM21: predicted level percentile 98.9%, R2 0.6663; pathway context only.
- KLK12: predicted level percentile 11.4%, R2 0.7889; pathway context only.
Candidate variants
- TYR rs1042602 CC: snpedia_context; Albinism or congenital nystagmus · Oculocutaneous albinism · SKIN/HAIR/EYE PIGMENTATION 3, LIGHT/DARK SKIN · Oculocutaneous albinism type 1B · Oculocutaneous albinism type 1A.
- BAG6 rs10484558 TT: snpedia_context.
Prostate and male cancer context
useful to review
Prostate cancer and prostate-marker signals are notable enough to keep in mind during age-appropriate care.
Full explanation
Because the subject metadata is male, the prostate findings are relevant. The profile includes elevated prostate cancer background and prostate-marker signals, with matching prostate-related protein context.
This is not a cancer finding and it is not a blood-test result. It means that age, family history, urinary symptoms, and clinician-guided screening decisions matter more than the genetic result alone.
Some broader cancer-related signals are mixed, so this card is focused on the prostate-specific convergence rather than implying a general cancer tendency.
This becomes worth reviewing if there is a family history of prostate cancer, urinary flow changes, nighttime urination, pelvic pain, abnormal prostate blood tests, or when reaching the age where routine prostate discussions normally begin.
What to watch forUse this as context for age-appropriate prostate discussions, especially if family history, urinary symptoms, or prostate blood-test changes are present.
Show technical evidence
Risk-score evidence
- prostate cancer: risk percentile 96.9%, coverage 87%, PGS001292.
- prostate specific antigenlevels: risk percentile 92.8%, coverage 84%, PGS003378.
- hyperplasia of prostate: risk percentile 16.7%, coverage 80%, PGS001338.
- number of self reported cancers: risk percentile 92.8%, coverage 88%, PGS001005.
Protein pathway context
- KLK3: predicted level percentile 91.8%, R2 0.6695; pathway context only.
- MSMB: predicted level percentile 12.5%, R2 0.5861; pathway context only.
- KLK12: predicted level percentile 11.4%, R2 0.7889; pathway context only.
Candidate variants
- Variant rs10505483 CC: snpedia_context.
- MSMB rs10993994 TT: snpedia_context.
Body composition and metabolic efficiency
useful to review
The metabolic picture is divergent: diabetes and lipid signals look favorable, while energy-rate and lean-mass signals suggest training and nutrition should be deliberate.
Full explanation
This is one of the more nuanced categories. Several diabetes and lipid-related signals are favorable, including type 2 diabetes, long-term glucose, cholesterol, and triglyceride context.
At the same time, body-composition signals point toward lower body mass, lower lean mass, lower water mass, and lower energy-rate background. That pattern does not say metabolism is unhealthy; it suggests that muscle, protein intake, and progressive training may matter more for performance and resilience.
There is also medication-processing context for cholesterol medicines if those ever become relevant. That does not mean such medicines are needed now.
This becomes worth reviewing if there are unexplained weight changes, difficulty gaining or preserving muscle, unusual fatigue with training, abnormal glucose or lipid labs, statin side effects, or a family history of metabolic disease.
What to watch forPrioritize progressive strength training, adequate meals, and lab-informed decisions rather than assuming low diabetes or lipid genetics remove the need for healthy habits.
Show technical evidence
Risk-score evidence
- basal metabolic rate: risk percentile 98.8%, coverage 96%, PGS003903.
- overweight obesity and other hyperalimentation: risk percentile 81.7%, coverage 100%, PGS001825.
- incident type 2 diabetes: risk percentile 3.5%, coverage 99%, PGS002779.
- glycated haemoglobin: risk percentile 10.5%, coverage 100%, PGS001953.
- high cholesterol: risk percentile 1.6%, coverage 90%, PGS000936.
- log triglycerides: risk percentile 19.9%, coverage 100%, PGS003801.
Protein pathway context
- SMPDL3A: predicted level percentile 97.6%, R2 0.5001; pathway context only.
- APOBR: predicted level percentile 82.8%, R2 0.67; pathway context only.
- INSL3: predicted level percentile 87.8%, R2 0.7312; pathway context only.
- FSHB: predicted level percentile 86.5%, R2 0.6068; pathway context only.
- LRPAP1: predicted level percentile 18%, R2 0.6658; pathway context only.
Candidate variants
- Variant rs10503669 CC: snpedia_context.
- Variant rs10105606 CC: snpedia_context.
- LOC101929615 rs10195252 TT: snpedia_context.
- PCSK5 rs11144688 GG: snpedia_context.
- Variant rs10938397 GG: snpedia_context.
Medication-response context
- SLCO1B1: Decreased Function, *15/*37; affected medicines include Simvastatin (myopathy risk), Atorvastatin, Rosuvastatin, Pravastatin.
Digestive, liver, and kidney chemistry
useful to review
Gut, liver-enzyme, biliary, urinary, and kidney-marker signals form a mixed chemistry and digestion theme.
Full explanation
This category brings together several kinds of evidence: liver-enzyme background, albumin and total-protein context, biliary tract signals, bowel-frequency and diverticular signals, gut-inflammatory signals, urinary stone context, and kidney-marker context.
The direction is mixed rather than a single clear disease story. Some signals point toward inflammation or digestive sensitivity, while others are blood-chemistry or urine-marker context.
The diet implication is to favor steady, low-irritant basics: fiber, minimally processed foods, hydration through food and fluids, and alcohol restraint. This is not a sign that a liver, kidney, or bowel condition is present.
This becomes worth reviewing if there are persistent abdominal symptoms, bowel-pattern changes, jaundice, right-upper-abdominal pain, kidney stones, abnormal liver or kidney labs, unusual urine protein findings, or family history of bowel or biliary disease.
What to watch forUse this as context if digestive symptoms, liver or kidney lab changes, urinary stones, or persistent bowel changes become relevant.
Show technical evidence
Risk-score evidence
- aspartate aminotransferase u l: risk percentile 98.8%, coverage 92%, PGS000673.
- alanine aminotransferase: risk percentile 88.7%, coverage 100%, PGS001940.
- gamma glutamyl transferase: risk percentile 91%, coverage 97%, PGS000817.
- albumin: risk percentile 93.2%, coverage 100%, PGS001886.
- total protein: risk percentile 87.7%, coverage 100%, PGS002001.
- other biliary tract disease: risk percentile 97.8%, coverage 100%, PGS001862.
Protein pathway context
- MEP1B: predicted level percentile 11.5%, R2 0.6752; pathway context only.
- MST1: predicted level percentile 19.9%, R2 0.6781; pathway context only.
- SMPDL3A: predicted level percentile 97.6%, R2 0.5001; pathway context only.
- LCP1: predicted level percentile 4.9%, R2 0.5128; pathway context only.
Candidate variants
- MIR22,MIR22HG,WDR81 rs11078597 TT: snpedia_context.
- LOC101928338 rs10767873 TT: snpedia_context.
- CPS1 rs1047891 CC: snpedia_context.
- APOA1-AS,SIK3 rs10047462 TT: snpedia_context.
Heart rhythm and electrical timing
background
Heart rhythm and electrical-timing signals are more notable than broader cholesterol or clotting risk signals.
Full explanation
The heart evidence is mixed. Some signals related to heart rhythm and electrical timing are elevated, including atrial flutter and timing measures from heart electrical activity.
By contrast, several broader cardiovascular signals look favorable, including clotting, cholesterol, heart failure, aortic size, and inherited cardiomyopathy context. That makes this less like a broad heart-risk finding and more like a rhythm-awareness finding.
The practical takeaway is not to assume a heart problem. It is to take palpitations, fainting, unexplained exercise intolerance, or rhythm findings seriously if they occur.
This becomes worth reviewing if there are palpitations, fainting, unexplained breathlessness, chest discomfort with exertion, abnormal heart tracing results, stimulant sensitivity, family history of rhythm problems, or new endurance-training symptoms.
What to watch forIf rhythm symptoms or abnormal heart-tracing results appear, share this inherited rhythm-timing context with a clinician.
Show technical evidence
Risk-score evidence
- qrs duration: risk percentile 93.8%, coverage 100%, PGS001948.
- atrial flutter: risk percentile 84.8%, coverage 89%, PGS001263.
- p duration: risk percentile 82.9%, coverage 100%, PGS001902.
- lv ejection fraction: risk percentile 81.5%, coverage 82%, PGS001412.
- high blood pressure age at diagnosis: risk percentile 86.3%, coverage 88%, PGS000935.
- circulatory disease nec: risk percentile 6.1%, coverage 100%, PGS001847.
Protein pathway context
- PDGFRB: predicted level percentile 12.6%, R2 0.5601; pathway context only.
- SFTPD: predicted level percentile 82.2%, R2 0.5378; pathway context only.
- APOBR: predicted level percentile 82.8%, R2 0.67; pathway context only.
Candidate variants
- LOC105377979 rs1015451 TT: snpedia_context.
- ADRB2 rs1042713 GG: snpedia_context; salmeterol response - Efficacy.
- ADRB2 rs1042714 GG: snpedia_context.
Mood, stress, and cognitive background
useful to review
Mood, worry, fatigue, stress reactivity, and research-only brain signals make mental recovery and sleep regularity important context.
Full explanation
Several signals cluster around mood, worry, depression background, stress sensitivity, loneliness, tiredness, and related traits. These are tendencies, not a statement about current mood or mental health.
There are also research-only brain-region signals. Those are useful as background, but they should not be treated as a medical-risk conclusion or a brain diagnosis.
A medication-processing finding is relevant if certain antidepressants or related medicines are ever considered, because inherited drug handling can affect prescribing decisions.
This becomes worth reviewing if there are persistent low mood, anxiety, loss of interest, sleep disruption, unusual fatigue, medication side effects, strong family history of mood disorders, or a meaningful change in work, relationships, or daily function.
What to watch forProtect sleep consistency and recovery, and share the medication-processing context if antidepressant treatment is ever discussed.
Show technical evidence
Risk-score evidence
- frequency of unenthusiasm disinterest in last 2 weeks: risk percentile 96.1%, coverage 89%, PGS001396.
- lifetime major depressive disorder: risk percentile 89.5%, coverage 98%, PGS000138.
- suffer from nerves: risk percentile 88.6%, coverage 90%, PGS001017.
- feelings of worry or anxiety: risk percentile 85.7%, coverage 92%, PGS001021.
- neuroticism score: risk percentile 93.2%, coverage 100%, PGS001996.
- loneliness: risk percentile 94.7%, coverage 86%, PGS001091.
Protein pathway context
- ADGRB3: predicted level percentile 99.6%, R2 0.597; pathway context only.
- DBH: predicted level percentile 2.9%, R2 0.6647; pathway context only.
- PDCD6: predicted level percentile 5.7%, R2 0.6598; pathway context only.
- CD33: predicted level percentile 88.2%, R2 0.7974; pathway context only.
- PSPN: predicted level percentile 13.2%, R2 0.5175; pathway context only.
Candidate variants
- Variant rs10789369 GG: snpedia_context.
- Variant rs10105606 CC: snpedia_context.
Medication-response context
- CYP2C19: Rapid Metabolizer, *1/*17; affected medicines include Clopidogrel, Omeprazole, Pantoprazole, Citalopram, Escitalopram, Voriconazole.
Hearing and sensory awareness
background
Hearing-difficulty signals are unusually strong, making hearing changes worth taking seriously if they appear.
Full explanation
The hearing-related findings are among the strongest single-lane results in the report. They include general hearing difficulty and hearing difficulty or deafness context.
This does not mean hearing loss is present. It means that noise exposure, ear symptoms, and age-related hearing changes may be more worth noticing.
There is also some eye and retinal background context, but the strongest signal here is hearing, so this card stays focused on sensory awareness rather than broad neurology.
This becomes worth reviewing if there is ringing in the ears, trouble hearing speech in noisy rooms, repeated loud-noise exposure, sudden hearing change, balance symptoms, family history of early hearing loss, or concerns from people around you.
What to watch forProtect hearing from loud noise and consider formal hearing review if real-world hearing changes, ringing, or balance symptoms appear.
Show technical evidence
Risk-score evidence
- hearing difficulty problems: risk percentile 99.9%, coverage 100%, PGS001891.
- hearing difficulty and deafness: risk percentile 92.1%, coverage 90%, PGS001252.
- hearing difficulty: risk percentile 91.5%, coverage 89%, PGS001253.
- wears glasses or contact lenses: risk percentile 80.9%, coverage 100%, PGS001924.
- retinal detachments and breaks: risk percentile 9.3%, coverage 85%, PGS000990.
- retinal detachments and defects: risk percentile 12.2%, coverage 100%, PGS001833.
Joint, bone, and connective tissue context
useful to review
Joint inflammation, knee arthrosis, osteoporosis, connective-tissue, and shorter-frame signals point toward careful strength progression.
Full explanation
This cluster overlaps with the immune findings but has enough musculoskeletal evidence to stand on its own. It includes inflammatory joint background, knee arthrosis, osteoporosis, connective-tissue context, and shorter-frame signals.
The practical meaning is not to avoid training. It is to train progressively, build joint capacity, and avoid sudden spikes in load that outpace tissue adaptation.
Protein-pathway context supports tissue structure and remodeling, but it is not a measured bone or tendon test. Real risk depends on injuries, pain, labs, imaging, nutrition, and training history.
This becomes worth reviewing if there is persistent joint swelling, morning stiffness, repeated tendon or ligament problems, low-trauma fracture, ongoing knee pain, back stiffness, family history of inflammatory arthritis, or abnormal bone-density results.
What to watch forUse progressive loading and joint-aware programming, and review this context if stiffness, swelling, fractures, or persistent joint pain occur.
Show technical evidence
Risk-score evidence
- osteoporosis: risk percentile 86.1%, coverage 100%, PGS001883.
- gonarthrosis arthrosis of knee: risk percentile 80.3%, coverage 90%, PGS001192.
- rheumatoid arthritis: risk percentile 89.3%, coverage 99%, PGS004010.
- polymyalgia rheumatica: risk percentile 90.7%, coverage 100%, PGS001878.
- other systemic involvement of connective tissue: risk percentile 92.3%, coverage 86%, PGS000960.
- arthritis: risk percentile 12.7%, coverage 88%, PGS001135.
Protein pathway context
- TNN: predicted level percentile 8.1%, R2 0.5604; pathway context only.
- PDGFRB: predicted level percentile 12.6%, R2 0.5601; pathway context only.
- AFAP1: predicted level percentile 15.7%, R2 0.5176; pathway context only.
Candidate variants
- PCSK5 rs11144688 GG: snpedia_context.
- Variant rs10865331 GG: snpedia_context.
Medication Safety
Genes below have pharmacogenomic phenotypes that may affect drug choice or dose review. Use this as a clinical discussion aid, not as a standalone prescribing instruction.
CYP2C19
RAPID METABOLIZER
*1/*17
Affected drugs: Clopidogrel, Omeprazole, Pantoprazole, Citalopram, Escitalopram, Voriconazole
CYP3A5
POOR METABOLIZER
*3/*3
Affected drugs: Tacrolimus, Sirolimus
SLCO1B1
DECREASED FUNCTION
*15/*37
Affected drugs: Simvastatin (myopathy risk), Atorvastatin, Rosuvastatin, Pravastatin
This report comes from consumer microarray data with statistical imputation. Confirm clinically before changing prescriptions.